Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships

Executive Summary

• Hemostemix Inc. announced the appointment of Dr. York Hsiang, a renowned vascular surgeon and former principal investigator on its Phase II ACP‑01 trial, as a Business Consultant.
• Dr. Hsiang will lead efforts to develop joint‑venture healthcare clinics on First Nations territories and advise on clinical staffing, commercialization pathways, and ethical scale‑up of the ACP‑01 therapy.
• The appointment underscores Hemostemix’s strategy to expand access to its autologous stem‑cell product (VesCell™/ACP‑01) in Canada, Florida (SB 1768), and The Bahamas, with a focus on underserved Indigenous communities.

Key Details

• Appointee: Dr. York Hsiang – Professor Emeritus of Surgery, University of British Columbia; former Principal Investigator for Hemostemix’s Phase II ACP‑01 trial.
• Role: Business Consultant to advise on:
• Joint ventures with First Nations governments for healthcare centers on sovereign territories.
• Clinical staffing models, physician engagement, and standards of care for ACP‑01 delivery.
• Strategic commercialization pathways in Canada, Florida (SB 1768), and The Bahamas.
• Ethical scale‑up of ACP‑01 for patients lacking conventional treatment options.
• Strategic Rationale: Aligns Hemostemix’s growth plan with Indigenous sovereignty, long‑term economic stewardship, capacity‑building, and culturally integrated care models.
• Clinical Background: Dr. Hsiang contributed to the Phase II trial that demonstrated 0 % five‑year mortality, cessation of pain, and 83 % wound‑healing rates in chronic limb‑threatening ischemia (CLTI) patients.
• Quotes:
• “Since 2006…the answer has been an enthusiastic ‘Yes’…in 30 years of medical practice I have not witnessed a therapy as effective as ACP‑01.” – Thomas Smeenk, President & CEO.
• “ACP‑01 is a dramatic game changer for suitable patients with no‑option CTLI…in 30 years of practice I have not seen a therapy as effective as ACP‑01.” – Dr. York Hsiang.

Notable Quotes

• Thomas Smeenk, President & CEO: “Since 2006, the first question I have asked every principal investigator I meet is simple: ‘Doctor, does ACP‑01 work?’ Without exception…the answer has been an enthusiastic ‘Yes’.”
• Dr. York Hsiang: “For peripheral arterial disease patients there are beneficial treatments…however, for no‑option CTLI patients a timely amputation was the only procedure offered. ACP‑01 is a dramatic game changer.”